PL439807A1 - Sposoby oczyszczania przeciwciał i ich kompozycje - Google Patents

Sposoby oczyszczania przeciwciał i ich kompozycje

Info

Publication number
PL439807A1
PL439807A1 PL439807A PL43980720A PL439807A1 PL 439807 A1 PL439807 A1 PL 439807A1 PL 439807 A PL439807 A PL 439807A PL 43980720 A PL43980720 A PL 43980720A PL 439807 A1 PL439807 A1 PL 439807A1
Authority
PL
Poland
Prior art keywords
compositions
methods
purifying antibodies
purifying
vedolizumab
Prior art date
Application number
PL439807A
Other languages
English (en)
Inventor
Sheldon F. Oppenheim
George PARKS
Norbert Schuelke
Lutifiye Kurt
Michael E. DOLAN
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of PL439807A1 publication Critical patent/PL439807A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/145—Extraction; Separation; Purification by extraction or solubilisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

W niniejszym zgłoszeniu przedstawiono sposoby oczyszczania humanizowanego przeciwciała anty-α4β7, takiego jak wedolizumab, wytwarzanego w hodowli komórek ssaków, podobnie jak kompozycje powstałe w wyniku wspomnianych procesów oczyszczania.
PL439807A 2019-06-10 2020-06-10 Sposoby oczyszczania przeciwciał i ich kompozycje PL439807A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962859580P 2019-06-10 2019-06-10
PCT/US2020/037069 WO2020252072A1 (en) 2019-06-10 2020-06-10 Antibody purification methods and compositions thereof

Publications (1)

Publication Number Publication Date
PL439807A1 true PL439807A1 (pl) 2022-12-05

Family

ID=73782230

Family Applications (1)

Application Number Title Priority Date Filing Date
PL439807A PL439807A1 (pl) 2019-06-10 2020-06-10 Sposoby oczyszczania przeciwciał i ich kompozycje

Country Status (14)

Country Link
US (1) US20220259291A1 (pl)
EP (1) EP3980119A4 (pl)
JP (2) JP7753105B2 (pl)
CN (4) CN118909121A (pl)
AR (1) AR119268A1 (pl)
AU (1) AU2020290999A1 (pl)
BR (1) BR112021024848A2 (pl)
CA (1) CA3143169A1 (pl)
IL (1) IL288830A (pl)
MA (1) MA56132A (pl)
MX (1) MX2021015302A (pl)
PL (1) PL439807A1 (pl)
TW (1) TW202112800A (pl)
WO (1) WO2020252072A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020020741A2 (pt) * 2018-04-10 2021-01-19 Dr. Reddy's Laboratories Limited Formulação farmacêutica estável de um anticorpo, e, formulação de anticorpo alfa4beta7 estável.
EP4380948A4 (en) * 2021-08-05 2025-07-16 Dr Reddys Laboratories Ltd METHOD FOR PURIFYING AN ANTIBODY COMPOSITION BY MEANS OF CATION EXCHANGE CHROMATOGRAPHY
WO2023031965A1 (en) * 2021-09-03 2023-03-09 Dr. Reddy’S Laboratories Limited Method to obtain a purified antibody composition
WO2023180523A1 (en) * 2022-03-24 2023-09-28 Pieris Pharmaceuticals Gmbh Process for purifying fusion proteins
TW202504919A (zh) 2023-05-30 2025-02-01 美商派拉岡醫療公司 α4β7整合素抗體組合物及使用方法
CN121889424A (zh) 2023-08-14 2026-04-17 派拉冈医疗公司 α4β7整联蛋白结合蛋白及使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
WO2006026759A2 (en) * 2004-09-03 2006-03-09 Genentech, Inc. Humanized anti-beta7 antagonists and uses therefor
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
TWI907924B (zh) * 2011-05-02 2025-12-11 日商武田藥品工業股份有限公司 抗-α4β7抗體之調配物
DK2970378T3 (da) * 2013-03-15 2021-08-23 Biogen Ma Inc Hydrofob interaktionsproteinkromatografi under saltfrie betingelser
SI3116891T1 (sl) * 2014-03-10 2020-07-31 Richter Gedeon Nyrt. Čiščenje imunoglobulina z uporabo predčistilnih stopenj
WO2018104893A1 (en) * 2016-12-06 2018-06-14 Glaxosmithkline Intellectual Property Development Limited Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life

Also Published As

Publication number Publication date
IL288830A (en) 2022-02-01
TW202112800A (zh) 2021-04-01
AU2020290999A1 (en) 2022-02-03
CN114025843A (zh) 2022-02-08
EP3980119A1 (en) 2022-04-13
JP2025087720A (ja) 2025-06-10
CN118909120A (zh) 2024-11-08
CN118909121A (zh) 2024-11-08
BR112021024848A2 (pt) 2022-01-18
CN118909119A (zh) 2024-11-08
CA3143169A1 (en) 2020-12-17
AR119268A1 (es) 2021-12-09
JP2022536659A (ja) 2022-08-18
MX2021015302A (es) 2022-01-18
US20220259291A1 (en) 2022-08-18
MA56132A (fr) 2022-04-13
EP3980119A4 (en) 2023-06-07
WO2020252072A1 (en) 2020-12-17
JP7753105B2 (ja) 2025-10-14
CN114025843B (zh) 2026-01-09

Similar Documents

Publication Publication Date Title
MX2021015302A (es) Metodos de purificacion de anticuerpos y composiciones de estos.
PL439808A1 (pl) Sposoby i kompozycje hodowli komórkowych do produkcji przeciwciał
JOP20230312A1 (ar) أجسام مضادة لـ ccr8 واستخداماتها
ECSP19087580A (es) Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
CR20210225A (es) RECEPTORES DE ANTÍGENES QUIMÉRICOS BASADOS EN ANTICUERPOS DE DOMINIO SIMPLE Y MÉTODOS DE USO DE ESTOS (Divisional 2018-0153)
EA201592192A1 (ru) Способ очистки моноклональных антител
BR112016014022A2 (pt) anticorpos anti-cd3, ácido nucleico isolado, vetor, célula hospedeira, método de produção do anticorpo anti-cd3, imunoconjugado, composição, uso do anticorpo anti-cd3, métodos de tratamento, métodos de intensificação da função imune e kit
SA523451582B1 (ar) Ccr8 الأجسام المضادة لـ
EA201992232A1 (ru) Композиции и способы для иммуноонкологии
DE602006006200D1 (de) Antikörper gegen 25-hydroxyvitamin d
MX368177B (es) Proceso continuo de múltiples etapas para purificar anticuerpos.
MX393951B (es) Anticuerpos antisortilina y métodos para su uso.
FI3683235T3 (fi) Anti-IL-33-vasta-aineita ja niiden käyttöjä
WO2017132627A3 (en) Screening methods for identifying antibodies that bind cell surface epitopes
SG10201810830UA (en) Cell culture compositions and methods for polypeptide production
WO2015127136A3 (en) Ebola monoclonal antibodies
BR112015022529A2 (pt) meios de cultura de células e processos de produção de anticorpo
AR119270A1 (es) MÉTODOS PARA PRODUCIR UN ANTICUERPO ANTI-a4b7
DE602005021379D1 (de) System und verfahren zur produktion von antikörpern in der pflanzenzellkultur
JOP20200295A1 (ar) أجسام أحادية النوعية ومتعددة النوعية مضادة لـ tmeff2 المضاد واستخداماتها
SA523450167B1 (ar) أجسام مضادة لعامل التحول الوسيطي الظهاري واستخداماتها
ZA202305072B (en) Cd1a antibodies and uses thereof
MX393714B (es) Anticuerpo para sesgar proporciones de sexos y metodos de uso del mismo.
JOP20210100A1 (ar) جسم مضاد أحادي النسيلة يرتبط على وجه التحديد بـ cd20
WO2016061608A8 (en) Monoclonal ανti-gpc-1 antibodies and uses thereof